Sector News

Shanghai Pharma bids for U.S. Cardinal Health's China business

October 19, 2017
Life sciences

Shanghai Pharmaceuticals Holding Co has bid for Cardinal Health Inc’s China business as the U.S. company looks to sell ahead of China’s planned drug distribution reform.

Shanghai Pharma submitted two non-binding bids to buy Cardinal Health China, one of the country’s largest drug distributors, on July 21 and Sept. 15, it said in a filing with the Shanghai stock exchange on Wednesday.

The company, backed by the Shanghai government, did not disclose the financial terms but said it has not entered into exclusive talks with the seller.

Reuters first reported in July that Cardinal Health had put its China business up for sale in a deal that could fetch between $1.2 billion and $1.5 billion.

The sale has drawn keen interest from state-backed Chinese pharmaceuticals companies and private equity firms such as FountainVest, said sources with knowledge of the matter.

Cardinal’s China business, which operates 16 distribution centers in 20 cities, generated more than $3.5 billion in revenue last year, compared with $3 billion in 2015, according to its earnings report.

It has hired Lazard as an adviser for the China sale, according to the sources.

FountainVest did not respond immediately to requests for comment and Lazard declined to comment. The sources asked not to be identified because the talks are not public.

Beijing in January introduced a so-called “two-invoice” procurement system for drug distribution on a trial basis as part of a broader overhaul of the country’s fragmented healthcare sector.

Under the new system, expected to be fully implemented in 2018, drug manufacturers can only work with a single distributor that directly supplies products to healthcare facilities such as hospitals.

The policy is likely to squeeze margins for many distributors that lack links to strong manufacturers and healthcare facilities in China.

In spite of the overhaul, state-owned pharma companies with strong backing from Beijing to create “national champions” in key industries have been looking to expand.

Shanghai Pharma, for example, said in August that it was bidding for a stake in U.S. specialty drugmaker Arbor Pharmaceuticals.

By Julie Zhu

Source: Reuters

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend